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ln some human cancer cases, the activity 01 p53 is inhibited by the overexpressed Mdm2 (E3 
ubiquitin-protein ligase Mdm2) oncoprotein.' Mdm2 acts as an ubiquitin ligase, resulting in p53 
ubiquitination and subsequent p53 proteasomal degradation. The disruption 01 the Mdm2-p53 
interaction using small-molecule inhibitors is recognized as a promising strategy for anticancer drug 
design.2 Mushrooms are a vast and yet largely untapped source 01 powerful new pharmaceutical 
products. ln particular, and most importantly lor modem medicine, they represent an unlimited source 
01 compounds with antitumor and immunostimulating properties.3 ln this study, a total 01 85 LMW (Iow 
molecular weight) compounds present in mushrooms were used in a protein-ligand docking 
experiment using a Mdm2 protein structure (PDB:1T4E) as receptor protein target. 
The 1T 4E X-ray structure presents Mdm2 co-crystallized with a known inhibitor, benzodiazepinedione, 
located in the Mdm2-p53 interaction site with an experimental Ki value 0180 nM.' AutoDock Vina, the 
docking tool used in this study, predicted a Ki value 01 79 nM and RMSD (Root Mean Standard 
Deviation) 01 0.033 A lor benzodiazepinedione, when compared to the cc-crystallized 
benzodiazepinedione, thus validating the 1T4E structure lar docking subsequent compounds. Virtual 
screening 01 the 85 LMW compounds was then performed. Ergosterol (Ki=824 nM) and ergosta-
4,6,8(1 4),22-tetraen-3-one (Ki=824 nM) stand out as the top ranked potential inhibitors lor Mdm2. 80th 
compounds were then manually inspected in arder to investigate its specific binding mode. The 
inlormation provided shows several interesting starting pOints for lurther development 01 Mdm2 
inhibitors. Furthermore, this study contributes to the valorisation af mushrooms as functional foods. 
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